Full text
Earnings transcript
Read the complete earnings call transcript.
SYK
Stryker Corporation
$331.54
2.14
(0.65%)
| Exchange: | NYSE |
| Market Cap: | 126.877B |
| Shares Outstanding: | 336M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Kevin A. Lobo | |||||
| Full Time Employees: | 53000 | |||||
| Address: |
| |||||
| Website: | https://www.stryker.com |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 20,498,000 | 22,595,000 | 25,116,000 |
| Gross Profit | 12,494,000 | 13,980,000 | 16,065,000 |
| EBITDA | 5,057,000 | 4,938,000 | 6,314,000 |
| Operating Income | 4,281,000 | 5,061,000 | 4,889,000 |
| Net Income | 3,165,000 | 2,993,000 | 3,246,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 39,912,000 | 42,971,000 | 47,844,000 |
| Total Liabilities | 21,319,000 | 22,337,000 | 25,424,000 |
| Total Stockholders Equity | 18,593,000 | 20,634,000 | 22,420,000 |
| Total Debt | 13,494,000 | 14,120,000 | 14,859,000 |
| Cash and Cash Equivalents | 2,971,000 | 3,652,000 | 4,011,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 3,711,000 | 4,242,000 | 5,044,000 |
| Capital Expenditure | -575,000 | -755,000 | -761,000 |
| Free Cash Flow | 3,136,000 | 3,487,000 | 4,283,000 |
| Net Income | 3,165,000 | 2,993,000 | 3,246,000 |
| Net Change in Cash | 1,127,000 | 681,000 | 359,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 37,165,418.191 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 38,338,777.977 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 37,846,750 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 8,513,330.152 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 8,782,106.874 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 8,669,400.040 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 8,614,734.514 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 8,970,260.777 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 8,821,176.023 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 12,512,196.911 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 12,907,222.970 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 12,741,575.677 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 23.080 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 23.470 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 22.540 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 13 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: SYK demonstrates strong revenue and net income growth as reported in recent income statements, supported by consistent operating cash flow and free cash flow figures from cash flow statements. This reflects operational efficiency and financial stability, positioning the company well within the medical devices industry.
- Market Leadership in Medical Technology: As highlighted in the company profile, SYK operates in the healthcare sector with a focus on innovative medical and surgical equipment. This aligns with industry trends toward advanced healthcare solutions, providing a competitive edge over peers, as evidenced by strong gross profit margins in key metrics.
- Global Revenue Diversification: Revenue geo segments data indicates a balanced distribution of revenue across multiple regions, reducing dependency on any single market and enhancing resilience against regional economic downturns.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates SYK intrinsic value between $133.06 – $246.02 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about SYK valuation
Is Stryker Corporation (SYK) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Stryker Corporation (SYK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SYK a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SYK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SYK’s P/E ratio?
You can see SYK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SYK?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SYK a good long-term investment?
Whether SYK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SYK
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.65
Trading Metrics:
| Open: | 327.32 | Previous Close: | 329.4 | |
| Day Low: | 324.03 | Day High: | 332.99 | |
| Year Low: | 319.32 | Year High: | 404.87 | |
| Price Avg 50: | 358.03 | Price Avg 200: | 370.56 | |
| Volume: | 1.485M | Average Volume: | 2.088M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeSYK full analysis
Welcome to MARKETSNAP’s SWOT analysis for Stryker Corporation, a heavyweight in the medical technology space. If you’re a long-term investor looking to build wealth through smart picks, you’re in the right place. Today, we’re diving deep into Stryker—known by its ticker SYK—unpacking what makes this company tick, where it shines, where it struggles, and what could shape its future. Let’s get into it with a quick overview, some recent updates, and then a full breakdown of strengths, weaknesses, opportunities, and…
